Publication: Multi-institutional Observational Study of Prophylactic Extended-Field Concurrent Chemoradiation Therapy Using Weekly Cisplatin for Patients With Pelvic Node-Positive Cervical Cancer in East and Southeast Asia
Issued Date
2019-09-01
Resource Type
ISSN
1879355X
03603016
03603016
Other identifier(s)
2-s2.0-85068438634
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Radiation Oncology Biology Physics. Vol.105, No.1 (2019), 183-189
Suggested Citation
Masaru Wakatsuki, Shingo Kato, Tatsuya Ohno, Parvin Akhter Banu, Nguyen Cong Hoang, Erdenetuya Yadamsuren, Nana Supriana, Jianping Cao, C. R.Beena Devi, Miriam Joy Calaguas, Yaowalak Chansilpa, Chul Koo Cho, Tasbolat Adylkhanov, Noriyuki Okonogi, Takashi Nakano, Hirohiko Tsujii Multi-institutional Observational Study of Prophylactic Extended-Field Concurrent Chemoradiation Therapy Using Weekly Cisplatin for Patients With Pelvic Node-Positive Cervical Cancer in East and Southeast Asia. International Journal of Radiation Oncology Biology Physics. Vol.105, No.1 (2019), 183-189. doi:10.1016/j.ijrobp.2019.04.039 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/50101
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Multi-institutional Observational Study of Prophylactic Extended-Field Concurrent Chemoradiation Therapy Using Weekly Cisplatin for Patients With Pelvic Node-Positive Cervical Cancer in East and Southeast Asia
Other Contributor(s)
The First Affiliated Hospital of Soochow University
Jichi Medical University
Semey Medical University
St. Luke's Medical Center Quezon City
University of Indonesia, RSUPN Dr. Cipto Mangunkusumo
Korea Institute of Radiological and Medical Sciences
Saitama Medical University
National Institute of Radiological Sciences Chiba
Faculty of Medicine, Siriraj Hospital, Mahidol University
Sarawak General Hospital
Gunma University Faculty of Medicine
Delta Hospitals Limited
National Cancer Center
National Cancer Hospital
Jichi Medical University
Semey Medical University
St. Luke's Medical Center Quezon City
University of Indonesia, RSUPN Dr. Cipto Mangunkusumo
Korea Institute of Radiological and Medical Sciences
Saitama Medical University
National Institute of Radiological Sciences Chiba
Faculty of Medicine, Siriraj Hospital, Mahidol University
Sarawak General Hospital
Gunma University Faculty of Medicine
Delta Hospitals Limited
National Cancer Center
National Cancer Hospital
Abstract
© 2019 Elsevier Inc. Purpose: This multi-institutional observational study conducted among 11 countries in East and Southeast Asia aimed to assess the clinical outcomes of prophylactic extended-field concurrent chemoradiation therapy using weekly cisplatin for patients with locally advanced cervical cancer. Methods and Materials: Between October 2007 and May 2016, 106 patients with untreated squamous cell carcinoma of the cervix were enrolled in the present study. Radiation therapy consisted of pelvic irradiation (total dose, 50 Gy in 25 fractions including central shielding), prophylactic paraortic regional irradiation (36-40 Gy in 20 fractions), and either high- or low-dose-rate intracavitary brachytherapy (ICBT) according to institutional practice. The planned point A dose was 21 to 28 Gy in 3 to 4 fractions for high-dose-rate ICBT and 40 to 41 Gy in 1 to 2 fractions for low-dose-rate ICBT. Five cycles of weekly cisplatin (40 mg/m2) were administered during the radiation therapy course. Results: A total of 106 patients were enrolled. Of these, 9 had major protocol violations and 2 did not receive treatment because of worsened general condition. Thus, 95 patients were evaluable. The median follow-up was 56 months. Of the 95 patients, 76 (80%) received 4 or 5 cycles of chemotherapy. Acute grade 3 leukopenia was observed in 20 of the patients (21%), and late grade 3 gastrointestinal toxicity was observed in 3%. The 2-year local control, progression-free survival, and overall survival rate for all patients were 96%, 78%, and 90%, respectively. Conclusions: The results indicated that prophylactic extended-field concurrent chemoradiation therapy using weekly cisplatin is feasible and effective for patients with locally advanced cervical cancer in East and Southeast Asia.